iA Global Asset Management Inc. Sells 53,580 Shares of Kenvue Inc. (NYSE:KVUE)

iA Global Asset Management Inc. trimmed its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 82.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,035 shares of the company's stock after selling 53,580 shares during the quarter. iA Global Asset Management Inc.'s holdings in Kenvue were worth $255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in KVUE. Leo Wealth LLC raised its stake in Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company's stock worth $3,507,000 after buying an additional 481 shares during the period. Alerus Financial NA raised its position in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company's stock worth $4,426,000 after purchasing an additional 491 shares during the period. Massmutual Trust Co. FSB ADV raised its position in shares of Kenvue by 6.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company's stock worth $194,000 after purchasing an additional 492 shares during the period. Wolff Wiese Magana LLC lifted its holdings in shares of Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company's stock worth $1,781,000 after purchasing an additional 501 shares in the last quarter. Finally, Marathon Capital Management increased its stake in Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company's stock valued at $2,722,000 after purchasing an additional 514 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

NYSE KVUE traded down $0.51 during trading hours on Wednesday, reaching $22.23. 9,433,236 shares of the company were exchanged, compared to its average volume of 17,686,359. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The business's 50 day simple moving average is $22.96 and its 200-day simple moving average is $21.15. The stock has a market capitalization of $42.62 billion, a P/E ratio of 41.35, a P/E/G ratio of 2.07 and a beta of 1.37. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the business earned $0.31 earnings per share. Kenvue's revenue for the quarter was down .4% on a year-over-year basis. On average, equities research analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.69%. The ex-dividend date was Wednesday, November 13th. Kenvue's dividend payout ratio is currently 149.09%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KVUE. JPMorgan Chase & Co. lifted their price objective on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They set a "buy" rating and a $27.00 price target for the company. Bank of America increased their price objective on Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. Royal Bank of Canada upgraded Kenvue from a "hold" rating to a "moderate buy" rating in a report on Monday. Finally, Piper Sandler increased their price target on Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.